NCT01384058View on ClinicalTrials.gov

Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

June 30, 2010

Conditions
Diabetes Mellitus Type 2Hypercholesterolemia
Interventions
DRUG

ezetimibe

ezetimibe 10 mg per day for six weeks

DRUG

simvastatin

Simvastatin 20 mg per day for six weeks

DRUG

Ezetimibe 10/Simvastatin 20

Ezetimibe 10mg/Simvastatin 20mg per day for six weeks

Trial Locations (2)

60322

Institut für Stoffwechselforschung, Frankfurt

78048

Stephan Jacob, MD, Villingen-Schwenningen

All Listed Sponsors
collaborator

Essex Pharma GmbH

INDUSTRY

lead

University Hospital Freiburg

OTHER

NCT01384058 - Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter